Direct medical expenditure associated with rheumatoid arthritis in a nationally representative sample from the medical expenditure panel survey

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Arthritis care & research

• Publication date

  2012-11-01

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1002/acr.21755PMID 22674912
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evaluation of Health Care Cost and Utilization Project Data (HCUP) in Healthcare Research

  2013cited by this paper
• Epidemiology and burden of illness of rheumatoid arthritis

  2012cited by this paper
• Cost‐effectiveness of biologic response modifiers compared to disease‐modifying antirheumatic drugs for rheumatoid arthritis: A systematic review

  2011cited by this paper
• Modeling Health Care Costs and Counts

  2010cited by this paper
• Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

  2010cited by this paper
• The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study

  2010cited by this paper
• Influence of Rheumatoid Arthritis on Employment, Function, and Productivity in a Nationally Representative Sample in the United States

  2010cited by this paper
• Clinical effectiveness of biologics in clinical practice

  2010cited by this paper
• EULAR (欧州リウマチ学会) 合成および疾患修飾性抗リウマチ生物学的製剤による関節リウマチ管理に関する推奨ガイドライン | 文献情報 | J-GLOBAL 科学技術総合リンクセンター

  2010cited by this paper
• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

  2010cited by this paper
• 计量经济分析 = Econometric analysis

  2009cited by this paper
• Changes in the rates of joint surgery among patients with rheumatoid arthritis in California, 1983–2007

  2009cited by this paper
• Out-of-pocket expenses and their burden in patients with rheumatoid arthritis.

  2009cited by this paper
• Trends in Medical Care Expenditures of US Adults with Arthritis and Other Rheumatic Conditions 1997 to 2005

  2009cited by this paper
• Risk adjustment performance of Charlson and Elixhauser comorbidities in ICD-9 and ICD-10 administrative databases

  2008cited by this paper
• Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy.

  2008cited by this paper
• American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

  2008cited by this paper
• Medical care expenditures and earnings losses among persons with arthritis and other rheumatic conditions in 2003, and comparisons with 1997.

  2007cited by this paper
• Costs of Rheumatoid Arthritis: New Estimates from the Human Capital Method and Comparison to the Willingness-to-Pay Method

  2007cited by this paper
• Rheumatoid arthritis: what does it cost and what factors are driving those costs? Results of a survey in a community‐derived population in Malmö, Sweden

  2007cited by this paper
• Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data

  2007cited by this paper
• Use of medication

  2007cited by this paper
• Tumor necrosis factor inhibitors for rheumatoid arthritis.

  2006cited by this paper
• Tumor necrosis factor inhibitors for rheumatoid arthritis.

  2006cited by this paper
• Use of biologics in rheumatoid arthritis: where are we going?

  2006cited by this paper
• Dealing with Skewed Data on Costs and Expenditures

  2006cited by this paper
• Work disability and its economic effect on 55-64-year-old adults with rheumatoid arthritis.

  2005cited by this paper
• Medical care expenditures and earnings losses of persons with arthritis and other rheumatic conditions in the United States in 1997: total and incremental estimates.

  2004cited by this paper
• The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study

  2004cited by this paper
• Employment and work disability in rheumatoid arthritis

  2004cited by this paper
• TECHNICAL WORKING PAPER SERIES GENERALIZED MODELING APPROACHES TO RISK ADJUSTMENT OF SKEWED OUTCOMES DATA

  2003cited by this paper
• Use of biologics for rheumatoid arthritis tempered by concerns over safety, cost.

  2003cited by this paper
• Estimating log models: to transform or not to transform?

  2001cited by this paper
• Stata Statistical Software: Release 7.

  2001cited by this paper
• Economic burden of rheumatoid arthritis: a systematic review.

  2000cited by this paper
• The costs of rheumatoid arthritis: an international long-term view.

  2000cited by this paper
• Work disability in an inception cohort of patients with seropositive rheumatoid arthritis: a 20 year study.

  1999cited by this paper
• An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline.

  1999cited by this paper
• Work disability in rheumatoid arthritis 10 years after the diagnosis.

  1999cited by this paper
• The logged dependent variable, heteroscedasticity, and the retransformation problem.

  1998cited by this paper
• Patterns of Health Care in Ontario Arthritis and Related Conditions An ICES Practice Atlas: The Economic Cost of Arthritis and Rheumatism in Canada.

  1998cited by this paper
• Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls.

  1997cited by this paper
• Direct medical costs unique to people with arthritis.

  1997cited by this paper
• American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis

  year unknowncited by this paper

• A novel neuroimmune modulation system for the treatment of rheumatoid arthritis

  2024influential citation
• New and Emerging Therapies: Review the Latest Advancements in Rheumatology Treatments, Including Biologic Therapies, Targeted Therapies, Regenerative Medicine, and Novel Drug Development, Assessing their Potential Benefits and Limitations

  2024cites this paper
• Predictors of Utilization Frequency of and Expenditure Amount for Chiropractic Care in U.S. Adults: A Retrospective Cohort Study.

  2024cites this paper
• Clinical safety and feasibility of a novel implantable neuroimmune modulation device for the treatment of rheumatoid arthritis: initial results from the randomized, double-blind, sham-controlled RESET-RA study

  2024influential citation
• Expenditure of biological drugs for rheumatoid arthritis treatment in the Brazilian public health system

  2023cites this paper
• The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States

  2022cites this paper
• Impact of noncommunicable diseases on direct medical costs and worker productivity, Saudi Arabia.

  2022cites this paper
• Health care costs of rheumatoid arthritis: A longitudinal population study

  2021cites this paper
• Economic impact of Juvenile Idiopathic Arthritis: a systematic review

  2021cites this paper
• Predictive analytics for step-up therapy: Supervised or semi-supervised learning?

  2021cites this paper
• Patient Characteristics and Indicators of Treatment Initiation with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis: A Claims Database Analysis

  2021cites this paper
• Clinical Outcomes of Patients with Rheumatoid Arthritis Treated in a Disease Management Program: Real-World Results

  2020cites this paper
• Economic burden of fatigue or morning stiffness among patients with rheumatoid arthritis: a retrospective analysis from real-world data

  2020cites this paper
• Clinical Outcomes of Patients with Rheumatoid Arthritis Treated in a Disease Management Program: Real-World Results

  2020cites this paper
• Clinical Outcomes of Patients with Rheumatoid Arthritis Treated in a Disease Management Program: Real-World Results

  2020cites this paper
• Evaluation of the Economic Benefit of Earlier Systemic Lupus Erythematosus (SLE) Diagnosis Using a Multivariate Assay Panel (MAP)

  2020influential citation
• A Vocational Rehabilitation Intervention Framework for People With Rheumatoid Arthritis

  2020cites this paper
• Estimation of direct cost of managing rheumatoid arthritis treatment to Pakistani patients using real‐world follow‐up data

  2019cites this paper
• Budget Impact of Funding an Intensive Diet and Exercise Program for Overweight and Obese Patients With Knee Osteoarthritis

  2019cites this paper
• Longitudinal associations of multimorbidity, disability and out-of-pocket health expenditures in households with older adults in Mexico: The study on global AGEing and adult health (SAGE).

  2019cites this paper
• Prevalence of comorbidities and their associations with health-related quality of life and healthcare expenditures in patients with rheumatoid arthritis

  2019cites this paper
• An increased disease burden of autoimmune inflammatory rheumatic diseases in Korea.

  2019cites this paper
• Antirheumatic Medicine Prescribing Patterns and Direct Medicine Costs in the South African Private Health Sector.

  2018cites this paper
• Leveraging healthcare utilization to explore outcomes from musculoskeletal disorders: methodology for defining relevant variables from a health services data repository

  2018cites this paper
• Repository corticotropin injection in patients with rheumatoid arthritis resistant to biologic therapies

  2018cites this paper
• Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis

  2018influential citation
• Consistent estimation of polychotomous treatment effects with selection-bias and unobserved heterogeneity using panel data correlated random coefficients model

  2018cites this paper
• Medical Care Costs Associated With Rheumatoid Arthritis in the US: A Systematic Literature Review and Meta‐Analysis

  2018cites this paper
• The Economic Burden of ACPA-Positive Status Among Patients with Rheumatoid Arthritis

  2018cites this paper
• Modelling the cost-effectiveness of tofacitinib for the treatment of rheumatoid arthritis in the United States

  2018cites this paper
• Healthcare resource utilization and costs among patients with rheumatoid arthritis on biologic therapies in Taiwan: A 1-year mirror-image study using a national claims database

  2018cites this paper
• Systematic Literature Review of the Economic Burden of Celiac Disease

  2018cites this paper
• Assessing the Impacts of an Aging Population on Rising Healthcare and Pharmaceutical Expenditures within the United States

  2018cites this paper
• Cost-effective analysis of disease-modifying anti-rheumatic drugs in rheumatoid arthritis

  2017cites this paper
• Comparing Healthcare Costs Associated with Oral and Subcutaneous Methotrexate or Biologic Therapy for Rheumatoid Arthritis in the United States.

  2017influential citation
• Welfare costs in patients with rheumatoid arthritis and their partners compared with matched controls: a register-based study

  2017cites this paper
• Changes in Healthcare Utilization After Etanercept Initiation in Patients with Rheumatoid Arthritis: A Retrospective Claims Analysis

  2017cites this paper
• Sociodemographic Determinants of Out-of-Pocket Expenditures for Patients Using Prescription Drugs for Rheumatoid Arthritis.

  2017cites this paper
• COMPARISON OF POST-MARKETING SURVEILLANCE APPROACHES REGARDING INFECTIONS RELATED TO TUMOR NECROSIS FACTOR (TNF) INHIBITORS

  2017cites this paper
• Sjögren's syndrome: managed care data from a large United States population highlight real-world health care burden and lack of treatment options.

  2017cites this paper
• Population aging and disability: Implications for vocational rehabilitation practice

  2017cites this paper
• Direct Medical Costs and Its Predictors in EMAR-II Cohort

  2017cites this paper
• Direct medical costs and their predictors in the EMAR-II cohort: "Variability in the management of rheumatoid arthritis and spondyloarthritis in Spain".

  2017cites this paper
• Update on biosimilars in rheumatology

  2017cites this paper
• Timing of rehabilitation on length of stay and cost in patients with hip or knee joint arthroplasty: A systematic review with meta-analysis

  2017cites this paper
• Comparative effectiveness of biologics for the management of rheumatoid arthritis: systematic review and network meta-analysis

  2016cites this paper
• Pharmacoeconomics of Biosimilars: What Is There to Gain from Them?

  2016cites this paper
• The association between social support and medication adherence in adults with rheumatoid arthritis

  2016cites this paper
• Bayesian Network Meta-Analysis for Biologic Therapies in Rheumatoid Arthritis

  2016cites this paper
• A 6-year trend of the healthcare costs of arthritis in a population-based cohort of older women

  2016cites this paper
• Direct and indirect resource use, healthcare costs and work force absence in patients with non‐infectious intermediate, posterior or panuveitis

  2016cites this paper
• Identification des grands utilisateurs de soins de santé chez les patients souffrant de la douleur chronique non cancéreuse et suivis en soins de première ligne

  2016cites this paper
• Cost of arthritis: a systematic review of methodologies used for direct costs

  2016influential citation
• Evaluation of Real-World Experience with Tofacitinib Compared with Adalimumab, Etanercept, and Abatacept in RA Patients with 1 Previous Biologic DMARD: Data from a U.S. Administrative Claims Database

  2016cites this paper
• Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.

  2016influential citation
• Costes médicos directos y sus predictores en la cohorte “Variabilidad en el manejo de la artritis reumatoide y las espondiloartritis en España”

  2016cites this paper
• Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States.

  2015cites this paper
• Versorgungsepidemiologie der rheumatoiden Arthritis in der vergangenen Dekade – Prognose, neue Behandlungsziele und aktuelle Kostenentwicklungen

  2015cites this paper
• Factors associated with higher healthcare costs in individuals living with arthritis: evidence from the quantile regression approach

  2015cites this paper
• Redox Regulation of Pro-IL-1β Processing May Contribute to the Increased Severity of Serum-Induced Arthritis in NOX2-Deficient Mice

  2015cites this paper
• Blood-based identification of non-responders to anti-TNF therapy in rheumatoid arthritis

  2015cites this paper
• Biosimilars for the management of rheumatoid arthritis: economic considerations

  2015cites this paper
• Evolution of cost structures in rheumatoid arthritis over the past decade

  2014cites this paper
• A Multistakeholder Approach to Improving Quality in Rheumatoid Arthritis: Proceedings from the Rheumatoid Arthritis Quality Expert Medical Panel.

  2014cites this paper
• Factors associated with withdrawal of the anti‐TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry

  2014cites this paper
• Evolution of Direct Costs in the First Years of Rheumatoid Arthritis: Impact of Early versus Late Biologic Initiation - An Economic Analysis Based on the ESPOIR Cohort

  2014cites this paper
• Comparative Effectiveness Research / HTA Evaluating Direct Medical Expenditures Estimation Methods of Adults Using the Medical Expenditure Panel Survey : An Example Focusing on Head and Neck Cancer

  2014cites this paper
• Evaluating direct medical expenditures estimation methods of adults using the medical expenditure panel survey: an example focusing on head and neck cancer.

  2014influential citation
• Economics of Non-Adherence to Biologic Therapies in Rheumatoid Arthritis

  2014cites this paper
• Incremental direct medical expenditures associated with anxiety disorders for the U.S. adult population: evidence from the Medical Expenditure Panel Survey.

  2013cites this paper
• Cost of Illness Study of Anxiety Disorders for the Ambulatory Adult Population of the United States

  2013cites this paper
• 2016). Direct and indirect resource use, healthcare costs and work force absence in patients with non-infectious intermediate, posterior or panuveitis. Acta Ophthalmologica

  year unknowncites this paper